We detected CXorf48-specific CTLs in the peripheral blood mononuclear cells from CML patients who have discontinued imatinib after maintaining complete molecular remission for more than 2 years. The gene discussed is CT55; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.